EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evolutionary dynamics of heparan sulfate utilization by SARS-CoV-2

Shuhei Higuchi iD, Yafei Liu, Jun Shimizu iD, Chikako Ono, Yumi Itoh, Wataru Nakai, Hui Jin, Kazuki Kishida, Kazuo Takayama iD, Toru Okamoto, Yoshiko Murakami, Taroh Kinoshita und 3 weitere

mBio · 2025

DOI: 10.1128/mbio.01303-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2025. Verfasst von Shuhei Higuchi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advanced Modalities and DDS, Osaka University, Suita, Osaka, Japan. Hauptthemen laut MEDLINE: Heparan Sulfate, SARS-CoV-2, Spike Glycoprotein, Coronavirus, COVID-19. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, Japan Science and Technology Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants have acquired enhanced infectivity compared to earlier variants. To elucidate the underlying molecular mechanisms, we conducted CRISPR library screening to identify cell surface molecules that interact with the Omicron spike protein. Our findings revealed a significantly higher affinity between the Omicron spike and cell surface heparan sulfate compared to the wild-type spike. This increased binding affinity enables Omicron variants to infect cells expressing low levels of ACE2, which are minimally infected by the wild-type virus. Mutational analysis of heparan sulfate binding sites on the Omicron spike protein, coupled with electrostatic potential mapping, suggested that the accumulation of positively charged mutations has contributed to the enhanced heparan sulfate binding. Comparative analysis of heparan sulfate binding among Omicron subvariants—including BA.1, BA.2, BA.4, BA.5, XBB.1, and BA.2.86—revealed that most are likely to bind efficiently to heparan sulfate, but potential heparan sulfate binding sites of the spike protein have shifted from the early Omicron variants to more recent ones. Furthermore, we discovered that cell surface heparan sulfate proteoglycans are cleaved by TMPRSS2, a protease essential for wild-type SARS-CoV-2 infection. These findings suggest that SARS-CoV-2 is evolving to enhance its infectivity by optimizing its interaction with cell surface heparan sulfate. IMPORTANCE The Omicron variant has evolved to become highly infectious by acquiring numerous mutations. Understanding the impact of these mutations can provide valuable insights into the drivers of viral evolution and aid in the development of improved viral surveillance and vaccines. Our study demonstrates that the Omicron variants contain mutations that enhance their ability to bind to heparan sulfate. Highly infectious human viruses often utilize heparan sulfate for infection, suggesting that heparan sulfate likely plays a crucial role in viral adaptation to human hosts. Furthermore, we found that cell surface heparan sulfate proteoglycans are sensitive to TMPRSS2, while most other cell surface proteins are resistant to TMPRSS2. Given that TMPRSS2 is known to enhance the infectivity of earlier severe acute respiratory syndrome coronavirus 2 variants but cleaves heparan sulfate proteoglycans, it is probable that the high heparan sulfate binding acquired by the Omicron variant contributes to its decreased infectivity against TMPRSS2-expressing cells compared to earlier variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heparan SulfateSARS-CoV-2Spike Glycoprotein, CoronavirusCOVID-19HumansBinding SitesProtein BindingEvolution, MolecularMutationAngiotensin-Converting Enzyme 2HEK293 Cells

Stichwörter der Autor:innen

OmicronSARS-CoV-2TMPRSS2heparan sulfate

Substanzen

Heparan SulfateSpike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2spike protein, SARS-CoV-2ACE2 protein, human

Autor:innen und Institutionen

  • Center for Advanced Modalities and DDS, Osaka University, Suita, Osaka, Japan.
  • Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
  • MiCAN Technologies Inc., Kyoto, Japan.
  • Center for Infectious Disease Education and Research, Osaka University, Suita, Osaka, Japan.
  • Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
  • Department of Microbiology, Juntendo University School of Medicine, Bunkyo, Tokyo, Japan.

ORCID-Profile: Shuhei Higuchi, Jun Shimizu, Kazuo Takayama, Yoshiharu Matsuura, Hisashi Arase

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science
  • Japan Science and Technology Agency

Zitieren

APA

Higuchi, S., Liu, Y., Shimizu, J., Ono, C., Itoh, Y., Nakai, W., Jin, H., Kishida, K., Takayama, K., Okamoto, T., Murakami, Y., Kinoshita, T., Matsuura, Y., Shioda, T., & Arase, H. (2025). Evolutionary dynamics of heparan sulfate utilization by SARS-CoV-2. mBio. https://doi.org/10.1128/mbio.01303-25

Vancouver

Higuchi S, Liu Y, Shimizu J, Ono C, Itoh Y, Nakai W, et al. Evolutionary dynamics of heparan sulfate utilization by SARS-CoV-2. mBio. 2025. doi:10.1128/mbio.01303-25

BibTeX
@article{Higuchi2025,
  author = {Higuchi, Shuhei and Liu, Yafei and Shimizu, Jun and Ono, Chikako and Itoh, Yumi and Nakai, Wataru and Jin, Hui and Kishida, Kazuki and Takayama, Kazuo and Okamoto, Toru and Murakami, Yoshiko and Kinoshita, Taroh and Matsuura, Yoshiharu and Shioda, Tatsuo and Arase, Hisashi},
  title = {Evolutionary dynamics of heparan sulfate utilization by SARS-CoV-2},
  journal = {mBio},
  year = {2025},
  doi = {10.1128/mbio.01303-25}
}
Kostenlos starten →